Re: Lung Cancer Risk and Radiation Dose Among Women Treated for Breast Cancer

Inskip et al. (1) were able to quantify the long-term risk of lung cancer in terms of radiation dose among 897,610-year survivors of breast cancer reported to the Connecticut Tumor Registry between 1935 and 1971. The relative risk of lung cancer following treatment with adjuvant radiotherapy and radical mastectomy was approximately twofold, based on 61 case patients. Radiation fields targeted regional lymph nodes and the chest wall, resulting in large average doses to the lungs (15.2 Gy, ipsilateral lung; 4.6 Gy, contralateral lung). Lung cancer risk increased with radiation dose \( P = .18 \). Radiotherapy treatments have changed in recent decades, however, employing smaller fields that result in lower radiation doses to lung (1).

We extend the analysis of secondary lung cancer risk after breast cancer utilizing data on more than 180,000 women reported to the population-based registries that comprise the Surveillance, Epidemiology, and End Results (SEER) Program (1973-1991) of the National Cancer Institute (NCI). Information that is routinely provided to these registries includes the first course of cancer-directed therapy according to one of several broad designations. The extent of radiotherapy, which determines lung exposure, is not specified; however, for several sites, including breast, initial surgery is further described. Breast-conserving surgery is typically accompanied by local radiotherapy, resulting in considerably lower radiation exposure to the lung than delivered with techniques employed in the past in conjunction with more extensive resection (1). Following prior convention within the SEER Program (2), we defined breast-conserving surgery as a partial or less-than-total mastectomy. All other surgical procedures, including mastectomy, were grouped as “non-breed-conserving surgery.” Because type of operation served as an imperfect surrogate for the extent of radiotherapy, some misclassification may result. A portion of breast cancer patients reported to the SEER Program were included in a previous study (3) of secondary lung neoplasia.

Among 182,122 2-month survivors of breast cancer diagnosed between January 1, 1973, and December 31, 1991, and treated surgically, 1198 cases of lung cancer were observed (Table 1). The risk of subsequent lung cancer increased with time to reach 1.93 (95% confidence interval [CI] = 1.48-2.47; \( P \) trend <.0001) among 5923 10-year survivors initially treated with radiotherapy and non-breed-conserving surgery. The twofold risk is in agreement with results from the Connecticut study (1). Excess risks of lung cancer among long-term survivors existed for small-cell carcinoma (observed-to-expected [O/E] ratio = 2.89; 95% CI = 1.71-4.56), squamous cell carcinoma (O/E = 2.55; 95% CI = 1.46-4.14), and adenocarcinoma (O/E = 1.62; 95% CI = 0.96-2.56). In contrast, elevated lung cancer risks were not evident among 128,534 women who were not treated with radiation.

Because breast-conserving surgery has been utilized only recently within the SEER program (average year, 1988), lung cancer risk could not be evaluated among long-term survivors. There was no increased risk, however, apparent up to about 10 years after treatment.

Our results confirm that past adjuvant radiotherapy, likely to deliver substantial doses of radiation to the lungs, is associated with a twofold risk of pulmonary neoplasia among 10-year survivors of breast cancer (1). Breast-conserving surgery and local adjuvant radiotherapy (2), which delivers lower doses to lung, might be expected to result in smaller risks of lung cancer among long-term survivors.

LOIS B. TRAVIS
ROCHELLE E. CURTIS
PETER D. INSKIP
Radiation Epidemiology Branch
Division of Cancer Etiology
BENJAMIN F. HANKEY
Cancer Statistics Branch
Division of Cancer Prevention and Control
National Cancer Institute
Bethesda, Md.

Journal of the National Cancer Institute, Vol. 87, No. 1, January 4, 1995
Table I. Risk of secondary lung cancer following adjuvant radiotherapy for breast cancer

<table>
<thead>
<tr>
<th>Time since diagnosis of breast cancer</th>
<th>2 mo to &lt;1 y</th>
<th>1-4 y</th>
<th>5-9 y</th>
<th>≥10 y</th>
</tr>
</thead>
<tbody>
<tr>
<td>No. of patients entering interval</td>
<td>182,122*</td>
<td>162,813</td>
<td>81,748</td>
<td>32,268</td>
</tr>
<tr>
<td>No. of person-years within interval</td>
<td>142,902</td>
<td>472,566</td>
<td>265,979</td>
<td>113,128</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary lung cancer</th>
<th>Observed</th>
<th>O/E</th>
<th>Observed</th>
<th>O/E</th>
<th>Observed</th>
<th>O/E</th>
<th>Observed</th>
<th>O/E</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery: non-breast-conserving†</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant radiotherapy (n = 26,201)</td>
<td>6</td>
<td>0.33‡</td>
<td>67</td>
<td>0.98</td>
<td>69</td>
<td>1.24</td>
<td>63</td>
<td>1.93‡,§</td>
</tr>
<tr>
<td>No radiotherapy (n = 128,534)</td>
<td>79</td>
<td>0.73‡</td>
<td>412</td>
<td>1.02</td>
<td>249</td>
<td>0.88‡</td>
<td>156</td>
<td>1.08</td>
</tr>
<tr>
<td>Surgery: breast-conserving¶</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adjuvant radiotherapy (n = 19,247)</td>
<td>18</td>
<td>1.10</td>
<td>36</td>
<td>0.76</td>
<td>10</td>
<td>1.02</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>No radiotherapy (n = 8,140)</td>
<td>8</td>
<td>1.06</td>
<td>19</td>
<td>1.01</td>
<td>6</td>
<td>1.76</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>

*Number represents 2-mo survivors of breast cancer diagnosed between January 1, 1973, and December 31, 1991, who were initially treated with surgery and reported to one of nine population-based registries participating in the SEER Program.
†Represents subcutaneous mastectomy, total mastectomy, modified radical/total mastectomy, radical mastectomy, and extended radical mastectomy.
‡P<.05.
§Trend for P <.0001.
¶Represents partial or less-than-total mastectomy (including segmental mastectomy, lumpectomy, quadrantectomy, wedge resection, nipple resection, excisional biopsy, and partial mastectomy not otherwise specified), with or without dissection of axillary lymph nodes.
||Given the relatively recent introduction of this surgical approach, sufficient numbers of long-term survivors are not yet available within the SEER Program to quantify the risk of secondary lung cancer.

References

Notes
†Editor’s note: SEER is a set of geographically defined, population-based central tumor registries in the United States, operated by local nonprofit organizations under contract to the NCI. Each registry annually submits its cases to the NCI on a computer tape. These computer tapes are then edited by the NCI and made available for analysis.

§Statistical tests and 95% CIs were based on the assumption that the observed numbers of second cancers followed a Poisson distribution. Test for homogeneity and linear trend were conducted according to the methods of Breslow et al. (4). All P values were two-sided.

Correspondence to: Lois B. Travis, M.D., National Institutes of Health, Executive Plaza North, Rm. 408, Bethesda, MD 20892.